Electromed (ELMD) investor relations material

Executive summary

• Achieved record net revenue of $73.8 million for FY 2026, up 15.3% year-over-year, and $19.4 million for Q4 FY 2026, up 11.6% from the prior year quarter, marking the 15th consecutive quarter of year-over-year revenue and profit growth.

• Operating income reached $13.9 million for FY 2026, a 43.7% increase year-over-year, and $3.8 million for Q4 FY 2026, up 26% from the prior year quarter.

• Net income for FY 2026 was $11.3 million ($1.30 per diluted share), up from $7.5 million ($0.85 per diluted share) in FY 2025.

• Maintains a well-capitalized balance sheet with no debt and significant cash reserves.

• CEO announced retirement effective April 2027, with succession planning underway.

Financial highlights

• FY 2026 revenues reached $73.8 million, up from $64.0 million in FY 2025; Q4 net revenue was $19.4 million, up 11.6% year-over-year.

• Gross profit for FY 2026 was $57.9 million (78.5% margin), up from $50.0 million (78.1%) in FY 2025.

• Operating income for FY 2026 was $13.9 million (18.8% margin), up from $9.7 million (15.1%).

• Net income for FY 2026 was $11.3 million; diluted EPS was $1.30.

• Cash provided by operations was $9.7 million; ended FY 2026 with $20.5 million in cash and no debt.

Outlook and guidance

• Projecting double-digit top-line growth and continued operating leverage for fiscal 2027, with a focus on expanding within the bronchiectasis market.

• Expects continued improvement in gross margins and plans to leverage commercial team and reimbursement expertise.

• Expanding sales force to 67 territories, including hospital account liaisons.

• Home care revenue per rep target for FY27 set at $1,050,000–$1,150,000.